Janice Mehnert, MD, Head of the Phase I Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, and the Head of the Melanoma Research Team, discusses the role that multiple biomarkers and the microbiome play in treatment decisions in oncology.
Janice Mehnert, MD, Head of the Phase I Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, and the Head of the Melanoma Research Team, discusses the role that multiple biomarkers and the microbiome play in treatment decisions in oncology.
Transcript
You’ve written about the importance of biomarkers and about the need for multiple biomarkers. Are you seeing progress in this area?
So, I think we’re seeing a lot of dedicated effort toward the sophisticated quality collection of tissue specimens. I think we are still rather far away from the holy grail of having a test we can run prospectively to tell us when we meet a patient what type of therapy that patient should have. But certainly, the importance of having those assessments is noted by the immunotherapy community.
The problem, as I’ve written, is the immune microenvironment is very dynamic, and having one assessment that captures everything that is relevant is rather challenging—and may be out of reach. But certainly, it’s a topic of hot research, and the value of it is very much recognized. I think that we’re working on it, but I think we are [a way off] from having hard tests we can order in clinical practice.
There have been many studies in the literature recently about the microbiome and the potential here both in diagnostic and therapeutic strategies in immunotherapy. How important is this area, in your opinion?
I think it’s very important—it’s important to understand under the relevance. I just came back from the society of Melanoma Research in Manchester, England, and both Drs Jennifer Wargo and Jennifer McQuade gave excellent talks in this area.
I think of the immune system in three parts. They’re not separate; they’re integrated:
Certainly, understanding the relevance of how an individual microbiome may be applicable to the response to immunotherapy and the development of the cancer is mind-boggling, but it’s a very, very important topic and we’re going to be hearing a lot about it as we move forward.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More